

# Clinical advances of RNAi therapy discussed at Oligonucleotide Therapeutics and Delivery Conference 2021

*SMI reports: Discussions will be centered around improving targeted therapy uniting the field's biggest players to share their opinions*

LONDON, LONDON BRIDGE , UNITED KINGDOM, June 17, 2021 /EINPresswire.com/ -- From optimizing particle size to choosing the right nanocarrier systems, [Oligonucleotide Therapeutics](#) and [Delivery](#) conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms.



Download a copy of your brochure to find out who will be speaking at the upcoming conference in September [www.oligonucleotide.co.uk/einpr4](http://www.oligonucleotide.co.uk/einpr4)  
CLINICAL ADVANCES OF RNAI THERAPY

Treating diseases with antibody oligonucleotide conjugates: Combining the selectivity of antibodies with the specificity of oligonucleotide drugs

- Antibody oligonucleotide conjugates utilize the selectivity of antibody delivery and the specificity of oligonucleotide therapeutics to treat diseases
- AOC1001 is designed to treat myotonic dystrophy type 1
- Other AOCs are in development to address muscle disease and other disorders

Arthur A Levin, Chief Scientific Officer, Avidity Biosciences Inc

Delivery of Novel siRNA constructs for treating cancer

- Treating siRNA payloads for cancer treatment
- Understanding the challenges of cell-specific delivery: how to get size and efficacy right?
- Choosing the appropriate delivery system

- Presenting success and future steps

David Evans, Chief Scientific Officer, Sirnaomics, Inc

Recent clinical progress with RNAi loaded KRAS-LODER for pancreatic tumour

- Introducing the RNAi loaded KRAS-LODER for targeting KRAS mutations
- Overviewing recent clinical success in phase II trials
- Presenting phase II clinical trials results including primary and secondary endpoints
- Outlining next steps of programme

Amotz Shemi, CEO, Silenseed

INT-1B3 (miR-193a-3p mimic): from bench-to-bedside

- Focus on microRNA R&D
- Success (bench-to-bedside) story for Oncology therapeutic intervention
- Preclinical to first in human study transition

Michel Janicot, CDO, InteRNA Technologies BV

Register online: [www.oligonucleotide.co.uk/einpr4](http://www.oligonucleotide.co.uk/einpr4)

Early bird offer register by 30th June and save £100

Proudly Sponsored by ChemGenes | Genscript | Tosoh Bioscience

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For more details and all delegate enquiries please contact Alia Malick on: +44 (0)20 7827 6168.

For media queries please contact Jinna Sidhu at [hsidhu@smi-online.co.uk](mailto:hsidhu@smi-online.co.uk) or call +44 (0)20 7827 6088.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu

SMi Group

02078276088

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/544069858>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.